Status:
UNKNOWN
New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia
Lead Sponsor:
Assiut University
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Brief Summary
Acute lymphoblastic leukemia , also known as acute lymphocytic leukemia, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts, causing d...
Detailed Description
In recent years, new pieces of information obtained through immunophenotyping, cytogenetics and genomic profiling. Chemotherapy resistance have contributed to a better understanding of the pathology o...
Eligibility Criteria
Inclusion
- 1\. New cases of patients with acute lymphocytic leukemia. 2. Evaluation of markers 15 days after induction.
Exclusion
- Patients died after induction
- Patients diagnosed as Non Hodgkin Lymphoma.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03249636
Start Date
December 1 2017
End Date
October 1 2019
Last Update
August 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt